Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $8.7 million.

  • Outlook Therapeutics' Cash & Equivalents rose 5216.67% to $8.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 million, marking a year-over-year increase of 5216.67%. This contributed to the annual value of $8.1 million for FY2025, which is N/A changed from last year.
  • As of Q4 2025, Outlook Therapeutics' Cash & Equivalents stood at $8.7 million, which was up 5216.67% from $8.1 million recorded in Q3 2025.
  • In the past 5 years, Outlook Therapeutics' Cash & Equivalents registered a high of $8.9 million during Q2 2025, and its lowest value of $5.7 million during Q4 2024.